In contrast, targeting TAM by inhibiting CSF-1R has been reported to decrease the numbers of pancreatic tumor-initiating cells and improves chemotherapeutic efficacy in vivo [124]. This evidence concerns the gene CSF1R and pancreatic neoplasm.